LCI - Not All Strategic Transformations Are Elite But This One Is
Having once traded on the AMEX at $20 per share and viewed as an innovative company with a novel technology designed to aid in developing controlled release and abuse-resistant opioids, the competitive environment dramatically changed for Elite Pharma (ELTP). Ultimately, their share price dropped into the pennies, as their once-promising future lay in tatters. Relegated to the OTC and its isle of misfit investors, Elite needed more than a comeback, the company needed a strategic transformation.
As long understood in business, the competitive environment is the most powerful driver of the need for